{
    "doi": "https://doi.org/10.1182/blood.V120.21.3761.3761",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=2220",
    "start_url_page_num": 2220,
    "is_scraped": "1",
    "article_title": "Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy ",
    "article_date": "November 16, 2012",
    "session_type": "632. Chronic Myeloid Leukemia - Therapy: Poster III",
    "topics": [
        "bcr-abl tyrosine kinase",
        "imatinib mesylate",
        "leukemia, myelocytic, chronic",
        "brachial plexus neuritis",
        "disease progression",
        "leukemia",
        "accelerated phase",
        "beta-glucuronidase",
        "cytarabine",
        "follow-up"
    ],
    "author_names": [
        "Benjamin Hanfstein, MD",
        "Valeria Shlyakhto",
        "Michael Lauseker",
        "Philipp Erben, MD",
        "Susanne Saussele, MD",
        "Alice Fabarius, PhD",
        "Ulrike Proetel, MD",
        "Susanne Schnittger, PhD",
        "Hans-Jochem Kolb, MD",
        "Stefan W. Krause",
        "Joerg Schubert, MD",
        "Hermann Einsele",
        "Mathias Ha\u0308nel, MD",
        "Jolanta Dengler, MD",
        "Christiane Falge, MD",
        "Lothar Kanz, MD",
        "Andreas Neubauer, MD",
        "Michael Kneba, MD, PhD",
        "Frank Stegelmann, MD",
        "Michael Pfreundschuh, MD",
        "Cornelius F. Waller, MD",
        "Karsten Spiekermann, PhD",
        "Gabriela M. Baerlocher, MD",
        "Markus Pfirrmann",
        "Joerg Hasford",
        "Wolf-Karsten Hofmann",
        "Ru\u0308diger Hehlmann, MD",
        "Andreas Hochhaus, MD",
        "Martin C. Mu\u0308ller, MD"
    ],
    "author_affiliations": [
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "MLL Mu\u0308nchner Leuka\u0308mielabor, Mu\u0308nchen, Germany, "
        ],
        [
            "Medizinische Klinik und Poliklinik III, Klinikum der Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "Medizinische Klinik 5, Universita\u0308tsklinikum Erlangen, Erlangen, Germany, "
        ],
        [
            "Klinik fu\u0308r Ha\u0308matologie, Onkologie und Palliativmedizin, Evangelische Krankenhaus, Hamm, Germany, "
        ],
        [
            "Medizinische Klinik und Poliklinik II, Universita\u0308tsklinikum, Wu\u0308rzburg, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin III, Klinikum, Chemnitz, Germany, "
        ],
        [
            "Innere Medizin V, Universita\u0308tsklinikum, Heidelberg, Germany, "
        ],
        [
            "Medizinische Klinik 5, Klinikum Nord, Nu\u0308rnberg, Germany, "
        ],
        [
            "Innere Medizin II, Universita\u0308tsklinikum, Tu\u0308bingen, Germany, "
        ],
        [
            "Klinik fu\u0308r Ha\u0308matologie, Zentrum Innere Medizin, Philipps-Universita\u0308t, Marburg, Germany, "
        ],
        [
            "II. Medizinische Klinik und Poliklinik, Universita\u0308tsklinikum Schleswig-Holstein, Kiel, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin III, Universita\u0308tsklinikum, Ulm, Germany, "
        ],
        [
            "Innere Medizin I, Universita\u0308tsklinikum des Saarlandes, Homburg, Germany, "
        ],
        [
            "Innere Medizin 1, Universita\u0308tsklinikum, Freiburg, Germany, "
        ],
        [
            "Medizinische Klinik und Poliklinik III, Klinikum der Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "Universita\u0308tsklinik fu\u0308r Ha\u0308matologie, Inselspital, Bern, Switzerland, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "Institut fu\u0308r Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universita\u0308t, Mu\u0308nchen, Germany, "
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ],
        [
            "III. Medizinische Klinik, Universita\u0308t Heidelberg, Medizinische Fakulta\u0308t, Mannheim, Germany, "
        ],
        [
            "Klinik fu\u0308r Innere Medizin II, Universita\u0308tsklinikum, Jena, Germany"
        ],
        [
            "III. Medizinische Klinik, Ha\u0308matologie und Onkologie, Universita\u0308tsmedizin Mannheim, Mannheim, Germany, "
        ]
    ],
    "first_author_latitude": "49.49133414999999",
    "first_author_longitude": "8.488715",
    "abstract_text": "Abstract 3761 Introduction: Early assessment of molecular and cytogenetic response at 3 months of imatinib treatment has been shown to predict survival and might trigger treatment intensification in slow responders who are supposed to harbor a BCR-ABL positive clone with inferior susceptibility to tyrosine kinase inhibition (Hanfstein et al., Leukemia 2012). BCR-ABL transcript levels at 3 months depend on levels at diagnosis and the subsequent decline under treatment. Which of both parameters determines the clinical course and allows for prediction of survival is unclear. The BCR-ABL/ABL ratio is supposed to be skewed for high values, e.g. >10%, due to the fact that ABL transcripts are also amplified from the fusion gene and in fact BCR-ABL/(ABL + BCR-ABL) is determined. Therefore, Beta-glucuronidase (GUS) was used as reference gene to determine high transcript levels at diagnosis. In addition, the linearity of the BCR-ABL/GUS scale allowed for an optimization of prognostic cut-off levels. We compared the significance of 1) BCR-ABL/GUS at diagnosis, 2) BCR-ABL/GUS at 3 months, 3) the individual reduction of transcripts given by (BCR-ABL/GUS at 3 months)/(BCR-ABL/GUS at diagnosis), and 4) the established 10% BCR-ABL/ABL landmark expressed on the international scale (BCR-ABL IS ). Patients and methods: A total of 337 patients (pts) were investigated. According to the protocol of the German CML study IV pts could have been pre-treated with imatinib up to 6 weeks before randomization. 56 pts with imatinib onset before initial blood sampling within the study were excluded from the analysis. A total of 281 evaluable patients (median age 51 years, range 17\u201385, 42% female) were treated with an imatinib-based therapy consisting of imatinib 400 mg/d (n=76), imatinib 800 mg/d (n=110) and combinations of standard dose imatinib with interferon alpha (n=84) and low-dose cytarabine (n=11). Median follow-up was 4.8 years (range 1\u201310). Transcript levels of BCR-ABL, ABL, and GUS were determined by quantitative RT-PCR from samples taken before imatinib onset (\u201cat diagnosis\u201d) and 3 month samples. Only patients expressing typical BCR-ABL transcripts (b2a2 and/or b3a2) were considered. Disease progression was defined by the incidence of accelerated phase, blastic phase or death from any reason. A landmark analysis was performed for progression free survival (PFS) and overall survival (OS) after dichotomizing patients by a cut-off optimized by the cumulative martingale residuals method. Results: The median BCR-ABL/GUS ratio was 15.5% at diagnosis (0.07\u2013271) and 0.62% at 3 months (0\u201334.7) reflecting a decline by 1.4 log. Disease progression was observed in 17 patients (6.0%), 14 of them died (5.0%). With regard to the above described parameters the following findings were observed: 1) at diagnosis no cut-off level could be identified for BCR-ABL/GUS ratios to separate two prognostic groups according to long-term PFS or OS. 2) At 3 months an optimized 2.8% BCR-ABL/GUS cut-off separated a high-risk group of 61 pts (22% of pts, 8-year PFS 78%, 8-year OS 81%) from a good-risk group of 220 pts (78% of pts, 8-year PFS 94%, 8-year OS 94%, p<0.001, respectively). 3) At 3 months an individual reduction of BCR-ABL transcripts to at least 40% (0.4 log) of the initial level separated best and divided a high-risk group of 33 pts (12% of pts, 8-year PFS 74%, 8-year OS 80%) from a good-risk group of 248 pts (88% of pts, 8-year PFS 93%, 8-year OS 93%, p<0.001, respectively). 4) When the established 10% BCR-ABL IS at 3 months was investigated, 63 pts were high-risk (22% of pts, 8-year PFS 82%, 8-year OS 85%) and 218 good-risk (78% of pts, 8-year PFS 91%, 8-year OS 93%, p=0.002 for PFS, p=0.011 for OS). Conclusions: Initial BCR-ABL transcript levels at diagnosis did not show prognostic significance. To predict survival at 3 months of treatment the absolute transcript level normalized by ABL or GUS can be used. Disclosures: Schnittger: MLL Munich Leukemia Laboratory: Equity Ownership. Hochhaus: Novartis, BMS, MSD, Ariad, Pfizer: Consultancy Other, Honoraria, Research Funding. Mu\u0308ller: Novartis, BMS: Consultancy, Honoraria, Research Funding."
}